SGD Pharma is proud to announce the conversion of one of our two high-efficiency furnaces at our Saint-Quentin-Lamotte (SQLM) manufacturing facility in France. This conversion is part of our ambitious global decarbonisation strategy and will help reduce our overall carbon emissions by two-thirds by 2040.
This project, which will reduce SQLM's CO2 emissions by almost 20%, includes two phases that will both reduce natural gas consumption and increase on-site electricity consumption.
The SQLM furnace conversion will accelerate the electrification of one of the two furnaces (with a 40% increase in electricity production), while the other furnace has been 100% electric for many years. The project will also reduce gas consumption in the forehearths by 50 %.
This ambitious investment project is partly financed by the French government under France 2030 (managed by ADEME) and partly by the European Union - Nextgenerationeu / REPOWEREU.